184 related articles for article (PubMed ID: 24859456)
1. TERT promoter mutations: gatekeeper and driver of hepatocellular carcinoma.
Pinyol R; Tovar V; Llovet JM
J Hepatol; 2014 Sep; 61(3):685-7. PubMed ID: 24859456
[No Abstract] [Full Text] [Related]
2. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nault JC; Mallet M; Pilati C; Calderaro J; Bioulac-Sage P; Laurent C; Laurent A; Cherqui D; Balabaud C; Zucman-Rossi J
Nat Commun; 2013; 4():2218. PubMed ID: 23887712
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutations in primary liver tumors.
Nault JC; Zucman-Rossi J
Clin Res Hepatol Gastroenterol; 2016 Feb; 40(1):9-14. PubMed ID: 26336998
[TBL] [Abstract][Full Text] [Related]
4. Multiple β-catenin mutations in hepatocellular lesions arising in Abernethy malformation.
Sorkin T; Strautnieks S; Foskett P; Peddu P; Thompson RJ; Heaton N; Quaglia A
Hum Pathol; 2016 Jul; 53():153-8. PubMed ID: 27038679
[TBL] [Abstract][Full Text] [Related]
5. Well-differentiated hepatocellular neoplasm of uncertain malignant potential.
Balabaud C; Bioulac-Sage P; Ferrell L; Kakar S; Paradis V; Quaglia A; Sempoux C; Thung S; Zucman-Rossi J
Hum Pathol; 2015 Apr; 46(4):634-5. PubMed ID: 25661243
[No Abstract] [Full Text] [Related]
6. Well-differentiated hepatocellular neoplasm of uncertain malignant potential--reply.
Bedossa P; Burt AD; Brunt E; Callea F; Clouston AD; Dienes HP; Goodman ZD; Gouw AS; Hubscher SG; Roberts EA; Roskams T; Terracciano L; Tiniakos DG; Torbenson MS; Wanless IR
Hum Pathol; 2015 Apr; 46(4):635-6. PubMed ID: 25732109
[No Abstract] [Full Text] [Related]
7.
Longerich T; Endris V; Neumann O; Rempel E; Kirchner M; Abadi Z; Uhrig S; Kriegsmann M; Weiss KH; Breuhahn K; Mehrabi A; Weber TF; Wilkens L; Straub BK; Rosenwald A; Schulze F; Brors B; Froehling S; Pellegrino R; Budczies J; Schirmacher P; Stenzinger A
Gut; 2019 Jul; 68(7):1287-1296. PubMed ID: 30901310
[TBL] [Abstract][Full Text] [Related]
8. Well-differentiated hepatocellular neoplasm of uncertain malignant potential: proposal for a new diagnostic category.
Bedossa P; Burt AD; Brunt EM; Callea F; Clouston AD; Dienes HP; Goodman ZD; Gouw AS; Hubscher SG; Roberts EA; Roskams T; Terracciano L; Tiniakos DG; Torbenson MS; Wanless IR
Hum Pathol; 2014 Mar; 45(3):658-60. PubMed ID: 24529331
[No Abstract] [Full Text] [Related]
9. Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis.
Calderaro J; Nault JC; Balabaud C; Couchy G; Saint-Paul MC; Azoulay D; Mehdaoui D; Luciani A; Zafrani ES; Bioulac-Sage P; Zucman-Rossi J
Mod Pathol; 2016 Jan; 29(1):43-50. PubMed ID: 26516697
[TBL] [Abstract][Full Text] [Related]
10. Well-differentiated hepatocellular neoplasm of uncertain malignant potential: proposal for a new diagnostic category--reply.
Kakar S; Evason KJ; Ferrell LD
Hum Pathol; 2014 Mar; 45(3):660-1. PubMed ID: 24529332
[No Abstract] [Full Text] [Related]
11. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
Nault JC; Calderaro J; Di Tommaso L; Balabaud C; Zafrani ES; Bioulac-Sage P; Roncalli M; Zucman-Rossi J
Hepatology; 2014 Dec; 60(6):1983-92. PubMed ID: 25123086
[TBL] [Abstract][Full Text] [Related]
12. Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
Pezzuto F; Izzo F; Buonaguro L; Annunziata C; Tatangelo F; Botti G; Buonaguro FM; Tornesello ML
Oncotarget; 2016 Aug; 7(34):54253-54262. PubMed ID: 27276713
[TBL] [Abstract][Full Text] [Related]
13. Frequent somatic TERT promoter mutations and CTNNB1 mutations in hepatocellular carcinoma.
Lee SE; Chang SH; Kim WY; Lim SD; Kim WS; Hwang TS; Han HS
Oncotarget; 2016 Oct; 7(43):69267-69275. PubMed ID: 27661004
[TBL] [Abstract][Full Text] [Related]
14. Correlation of exon 3 β-catenin mutations with glutamine synthetase staining patterns in hepatocellular adenoma and hepatocellular carcinoma.
Hale G; Liu X; Hu J; Xu Z; Che L; Solomon D; Tsokos C; Shafizadeh N; Chen X; Gill R; Kakar S
Mod Pathol; 2016 Nov; 29(11):1370-1380. PubMed ID: 27469330
[TBL] [Abstract][Full Text] [Related]
15. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.
Zucman-Rossi J; Jeannot E; Nhieu JT; Scoazec JY; Guettier C; Rebouissou S; Bacq Y; Leteurtre E; Paradis V; Michalak S; Wendum D; Chiche L; Fabre M; Mellottee L; Laurent C; Partensky C; Castaing D; Zafrani ES; Laurent-Puig P; Balabaud C; Bioulac-Sage P
Hepatology; 2006 Mar; 43(3):515-24. PubMed ID: 16496320
[TBL] [Abstract][Full Text] [Related]
16. Telomerase reverse transcriptase promoter methylation is related to a risk of recurrence in hepatocellular carcinoma.
Ko E; Jung ES; Jung G
Hepatology; 2016 Jan; 63(1):341. PubMed ID: 25847141
[No Abstract] [Full Text] [Related]
17. [Hepatocellular carcinoma in an inflammatory adenoma with β-catenin mutation in a patient with hepatocellular adenomatosis due to germline mutation in HNF1α].
Ridder DA; Duret D; Wörns MA; Schotten S; Heinrich S; Kloth M; Springer E; Roth W; Straub BK
Z Gastroenterol; 2019 Jan; 57(1):46-51. PubMed ID: 30641602
[TBL] [Abstract][Full Text] [Related]
18. Cell biological evaluation of liver cell carcinoma, dysplasia and adenoma by tissue micro-array analysis.
van Dekken H; Verhoef C; Wink J; van Marion R; Vissers KJ; Hop WC; de Man RA; IJzermans JN; van Eijck CH; Zondervan PE
Acta Histochem; 2005; 107(3):161-71. PubMed ID: 16000213
[TBL] [Abstract][Full Text] [Related]
19. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
Torrecilla S; Sia D; Harrington AN; Zhang Z; Cabellos L; Cornella H; Moeini A; Camprecios G; Leow WQ; Fiel MI; Hao K; Bassaganyas L; Mahajan M; Thung SN; Villanueva A; Florman S; Schwartz ME; Llovet JM
J Hepatol; 2017 Dec; 67(6):1222-1231. PubMed ID: 28843658
[TBL] [Abstract][Full Text] [Related]
20. Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression.
Rebouissou S; Franconi A; Calderaro J; Letouzé E; Imbeaud S; Pilati C; Nault JC; Couchy G; Laurent A; Balabaud C; Bioulac-Sage P; Zucman-Rossi J
Hepatology; 2016 Dec; 64(6):2047-2061. PubMed ID: 27177928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
